TACR1 and rhabdoid tumor: In order to investigate possible synergism of conventional treatment regimens and NK1R-targeted therapies, we combined aprepitant with cisplatin, a commonly used cytostatic chemotherapeutic agent for the treatment of rhabdoid tumors [1,37].